BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27427770)

  • 1. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin.
    Prudnikova TY; Chernoff J
    Small GTPases; 2017 Oct; 8(4):193-198. PubMed ID: 27427770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.
    Prudnikova TY; Villamar-Cruz O; Rawat SJ; Cai KQ; Chernoff J
    Oncogene; 2016 Apr; 35(17):2178-85. PubMed ID: 26257058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
    Schraml P; Schwerdtfeger G; Burkhalter F; Raggi A; Schmidt D; Ruffalo T; King W; Wilber K; Mihatsch MJ; Moch H
    Am J Pathol; 2003 Sep; 163(3):985-92. PubMed ID: 12937139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.
    Ong CC; Gierke S; Pitt C; Sagolla M; Cheng CK; Zhou W; Jubb AM; Strickland L; Schmidt M; Duron SG; Campbell DA; Zheng W; Dehdashti S; Shen M; Yang N; Behnke ML; Huang W; McKew JC; Chernoff J; Forrest WF; Haverty PM; Chin SF; Rakha EA; Green AR; Ellis IO; Caldas C; O'Brien T; Friedman LS; Koeppen H; Rudolph J; Hoeflich KP
    Breast Cancer Res; 2015 Apr; 17(1):59. PubMed ID: 25902869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
    Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
    Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
    Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
    Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P21 activated kinase signaling in cancer.
    Rane CK; Minden A
    Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of 11q13 in ovarian carcinoma.
    Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
    Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p21-activated kinase inhibitors.
    Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
    Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
    Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
    Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
    Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
    Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.
    Ong CC; Jubb AM; Haverty PM; Zhou W; Tran V; Truong T; Turley H; O'Brien T; Vucic D; Harris AL; Belvin M; Friedman LS; Blackwood EM; Koeppen H; Hoeflich KP
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7177-82. PubMed ID: 21482786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
    Tabusa H; Brooks T; Massey AJ
    Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.
    Ma Y; McCarty SK; Kapuriya NP; Brendel VJ; Wang C; Zhang X; Jarjoura D; Saji M; Chen CS; Ringel MD
    J Clin Endocrinol Metab; 2013 Aug; 98(8):E1314-22. PubMed ID: 23709653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
    Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
    J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
    Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
    Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of p21-activated kinases (PAKs).
    Rudolph J; Crawford JJ; Hoeflich KP; Wang W
    J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
    Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
    J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.
    Liu JS; Che XM; Chang S; Qiu GL; He SC; Fan L; Zhao W; Zhang ZL; Wang SF
    World J Gastroenterol; 2015 Sep; 21(34):9945-56. PubMed ID: 26379399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways.
    Huynh N; Liu KH; Baldwin GS; He H
    Biochim Biophys Acta; 2010 Sep; 1803(9):1106-13. PubMed ID: 20595063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.